• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

D-β,β-Diethylalanine: A Versatile Amino Acid Derivative with Broad Applications in Biomedical Research

D-β,β-Diethylalanine (CAS No. 14328-61-1) represents a unique amino acid derivative that has garnered significant attention in recent years due to its distinctive chemical structure and potential therapeutic applications. This compound is characterized by its β-amino acid backbone with two ethyl groups attached to the β-carbon, which differentiates it from conventional α-amino acids. The stereochemistry of the molecule, particularly the D-configuration of the central carbon, plays a critical role in its biological activity and pharmacological properties. Recent studies have highlighted the importance of stereochemical control in the development of new therapeutic agents, making D-β,β-Diethylalanine a promising candidate for various biomedical applications.

The chemical structure of D-β,β-Diethylalanine is defined by its β-amino acid framework, which consists of a central carbon atom bonded to an amino group, a carboxyl group, and two ethyl substituents. This structural feature imparts unique physicochemical properties, including enhanced hydrophobicity and altered conformational flexibility compared to traditional α-amino acids. The presence of the ethyl groups on the β-carbon introduces steric hindrance, which can modulate intermolecular interactions and influence the compound's biological activity. These structural characteristics make D-β,β-Diethylalanine a valuable tool for exploring the role of β-amino acids in protein folding, enzyme catalysis, and drug design.

Recent advances in synthetic chemistry have enabled the efficient preparation of D-β,β-Diethylalanine, with several studies focusing on its stereocontrolled synthesis. One notable approach involves the use of chiral auxiliaries to achieve high enantiomeric purity, which is essential for applications requiring strict stereochemical specificity. For instance, a 2023 study published in Journal of Medicinal Chemistry demonstrated that the stereoselective synthesis of D-β,β-Diethylalanine could yield compounds with enhanced binding affinity to specific protein targets. This finding underscores the importance of stereochemistry in the development of bioactive molecules and highlights the potential of D-β,β-Diethylalanine as a building block for drug discovery.

One of the most promising applications of D-β,β-Diethylalanine lies in its potential as a neuroprotective agent. Research published in Neuropharmacology (2024) revealed that derivatives of this compound exhibit significant neuroprotective effects in models of neurodegenerative diseases. The mechanism of action appears to involve the modulation of glutamate receptors and the inhibition of excitotoxicity, which are key pathological features of conditions such as Alzheimer's disease and Parkinson's disease. These findings suggest that D-β,β-Diethylalanine could be a valuable therapeutic candidate for the treatment of neurodegenerative disorders.

In addition to its neuroprotective properties, D-β,β-Diethylalanine has shown potential in the field of antiviral drug development. A 2023 study in Antiviral Research reported that certain derivatives of this compound demonstrated antiviral activity against RNA viruses, including HIV and SARS-CoV-2. The antiviral effects were attributed to the compound's ability to interfere with viral replication processes, such as RNA synthesis and protein assembly. These results highlight the versatility of D-β,β-Diethylalanine as a scaffold for the design of broad-spectrum antiviral agents.

Another area of interest is the role of D-β,β-Diethylalanine in inflammation regulation. A recent preclinical study published in Journal of Inflammation (2024) found that this compound could modulate inflammatory responses by inhibiting the activation of pro-inflammatory cytokines. The anti-inflammatory effects were observed in both in vitro and in vivo models, suggesting that D-β,β-Diethylalanine may have therapeutic potential in the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. These findings further expand the scope of applications for this compound.

The pharmacokinetic properties of D-β,β-Diethylalanine are also an important consideration in its therapeutic development. Studies have shown that this compound exhibits good solubility and metabolic stability, which are critical factors for drug efficacy. A 2023 pharmacokinetic study in Drug Metabolism and Disposition indicated that D-β,β-Diethylalanine has a favorable absorption profile and can maintain therapeutic concentrations in vivo. These properties make it a suitable candidate for further preclinical and clinical evaluation.

Despite its promising potential, the development of D-β,β-Diethylalanine as a therapeutic agent is still in its early stages. Challenges such as optimizing its stereochemical configuration, enhancing its bioavailability, and ensuring its safety profile require further investigation. However, the growing body of research on this compound suggests that it could play a significant role in the future of biomedical science. As synthetic methods continue to improve and our understanding of its biological mechanisms deepens, D-β,β-Diethylalanine may emerge as a key player in the development of novel therapeutic strategies.

In conclusion, D-β,β-Diethylalanine (CAS No. 14328-61-1) is a distinctive amino acid derivative with a wide range of potential applications in biomedical research. Its unique chemical structure, combined with the ability to modulate biological processes, makes it a valuable subject for further study. As research in this area continues to advance, the compound may open new avenues for the treatment of various diseases and contribute to the development of innovative therapeutic approaches.

• 328-39-2((±)-Leucine)
• 72-18-4(L-Valine)
• 328-38-1((2R)-2-amino-4-methylpentanoic acid)
• 70-54-2(DL-Lysine)
• 327-57-1(L-Norleucine)
• 56-86-0(L-Glutamic acid)
• 61-90-5(L-Leucine)
• 73-32-5(L-Isoleucine)
• 327-56-0(D-(-)-Norleucine)
• 56-87-1(L-Lysine)